Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:811-813, 2002
© 2002 European Society for Medical Oncology


News

Bad news for taxpayers, good news for patients, in the UK

Chancellor Gordon Brown announced, in April 2002, that spending on the national health service (NHS) in the UK will exceed £100 billion in 5 years time (Table 1). ($1 {approx} £0.62; http://www.ecb.int/home/eurofxref.htm). This means spending would increase by an average of 7.4% in real terms for each of the next 5 years—funded in part by a 1% increase in national insurance contributions. More impressively, over the 5 years, the NHS budget will rise by 43% in real terms, and will have doubled since 1997. Mr Brown dismissed calls for alternative funding methods for the health service; general taxation was the equitable option, he said.


View this table:
[in this window]
[in a new window]
 
Table 1. UK government spending
 
Mr Brown said the increase in NHS investment would be pegged to reform, including a new system of independent scrutiny of patient complaints. New financial incentives for hospital performance, greater freedom for high performing hospitals and trusts, devolution of power and resources to . . . [Full Text of this Article]

Assisted suicide, euthanasia, mercy killing...

Investing in ‘pharma’ part 1

Investing in ‘pharma’ part 2

NIH Director and Surgeon General

Swiss drug costs are among the highest in Europe

Perhaps not everyone knows that...

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?